January 7, 2026
France's pharmacy network is being put to the test: in ten years, almost 10% of pharmacies have closed (i.e. around 2,000 dispensaries). In some rural communities, this trend is leading to the risk of a pharmaceutical desert.
In response, an experimental solution has been developed: pharmacy antennas.
The very first pharmacy outpost was administratively authorized in 2022 in Tende (Alpes-Maritimes), in a very particular context: the village had just been hit by flooding following storm Alex. The project, supported by ARS PACA and the local CPTS, aimed to re-establish access to healthcare for the commune's inhabitants, but due to a lack of recruitment, the experiment struggled to find its stride and never saw the light of day.
Since the enactment of the Valletoux law on December 27, 2023, antennas have benefited from a clear legal framework. The experiment, steered by the DGOS and the ARS, currently involves six pilot regions:
A total of 6 projects have been approved. Four branches are already operational, and further openings are planned in the coming months.
The experiment is governed by precise specifications. Among the main conditions:
Opening hours vary according to the project, from a minimum of 2 half-days (8h) per week (La Chapelle d'Anguillon), to a minimum of 4 days (32h) per week (Coupiac).
On the basis of current projects, an initial profile can be drawn up:
The experiment has raised both expectations and reservations.
In Cozzano (Corsica), the parent pharmacy had to deal with unprecedented administrative and billing difficulties with the CPAM.
Other pharmacists, such as Angélique Siettel (Loire), point out the logistical complexities: finding premises, the need to recruit, adapting software, coordinating with wholesalers...
The unions are of two minds:
Is this a miracle solution to a weakening regional network, or will it open the door to excesses that will make it even more fragile? This is the long-awaited answer that this experiment will provide, and it's one that we'll be watching closely, with a potentially major impact on the pharmaceutical landscape in the years to come.